Go Pro

OmniAb (NASDAQ:OABI) Sets New 12-Month High - Still a Buy?

OmniAb logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • OmniAb shares hit a new 52-week high, trading around $4.68 after rising 8.8%; the stock remains well above its 50-day and 200-day moving averages.
  • Analyst sentiment is mixed: HC Wainwright maintained a Buy rating with an $11 target, while the overall consensus is Hold from two Buy ratings and one Sell rating.
  • The company beat quarterly expectations, reporting a $0.05 per-share loss versus the expected $0.12 loss and revenue of $13.41 million versus $4.69 million expected, though it continues to post deeply negative margins and forecasts a full-year loss.
  • MarketBeat previews top five stocks to own in September.

OmniAb, Inc. (NASDAQ:OABI - Get Free Report)'s share price reached a new 52-week high on Monday . The stock traded as high as $4.65 and last traded at $4.6840, with a volume of 1415824 shares trading hands. The stock had previously closed at $4.33.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of OmniAb in a research note on Monday, August 17th. Weiss Ratings raised shares of OmniAb from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $11.00.

Read Our Latest Analysis on OmniAb

OmniAb Stock Up 8.8%

The company's 50-day simple moving average is $2.52 and its 200 day simple moving average is $2.09. The company has a market capitalization of $681.91 million, a P/E ratio of -13.08 and a beta of 0.45.

OmniAb (NASDAQ:OABI - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.07. The business had revenue of $13.41 million during the quarter, compared to analyst estimates of $4.69 million. OmniAb had a negative net margin of 115.12% and a negative return on equity of 16.59%. As a group, equities research analysts forecast that OmniAb, Inc. will post -0.35 earnings per share for the current year.

Institutional Trading of OmniAb

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. raised its stake in shares of OmniAb by 214.4% in the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company's stock valued at $25,000 after acquiring an additional 9,716 shares in the last quarter. AQR Capital Management LLC bought a new stake in OmniAb during the first quarter worth approximately $25,000. Legal & General Group Plc bought a new stake in OmniAb during the second quarter worth approximately $28,000. BNP Paribas Financial Markets grew its holdings in OmniAb by 92.5% during the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company's stock valued at $35,000 after purchasing an additional 10,438 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in OmniAb during the second quarter valued at approximately $37,000. Institutional investors and hedge funds own 72.08% of the company's stock.

About OmniAb

(Get Free Report)

OmniAb, Inc NASDAQ: OABI operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in OmniAb Right Now?

Before you consider OmniAb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.

While OmniAb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines